Court Upholds The Validity And Determined Actavis' Infringement Of Patent Protecting RELISTOR® Tablets
Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company") and Progenics Pharmaceuticals (NASDAQ:PGNX), announced today that the U.S. District Court of New Jersey upheld the validity and determined Actavis' infringement of a patent protecting RELISTOR® (methylnaltrexone bromide) tablets, expiring March 2031.
Defendant, Actavis Laboratories FL, Inc., a subsidiary of Teva Pharmaceutical Industries Ltd, had challenged the validity of and had alleged non-infringement of Claims 2 and 5 of U.S. Patent No. 8,524,276, which protects the formulation of RELISTOR® tablets.
Bausch Health is not aware of any other ANDAs filed with the FDA seeking approval of a generic version of RELISTOR tablets, and will continue to vigorously defend its intellectual property in these and other claims.
About ProgenicsProgenics is an oncology company focused on the development and commercialization of innovative targeted medicines and artificial intelligence to find, fight and follow cancer, including: therapeutic agents designed to treat cancer (AZEDRA®, 1095, and PSMA TTC); prostate-specific membrane antigen ("PSMA") targeted imaging agents for prostate cancer (PyL(TM) and 1404); and imaging analysis technology (aBSI and PSMA AI). Progenics has two commercial products, AZEDRA, for the treatment of patients with unresectable, locally advanced or metastatic pheochromocytoma or paraganglioma (rare neuroendocrine tumors of neural crest origin) who require systemic anticancer therapy; and RELISTOR® (methylnaltrexone bromide) for the treatment of opioid-induced constipation, which is partnered with Bausch Health Companies Inc.
About Bausch HealthBausch Health Companies Inc. (NYSE/TSX: BHC) is a global company whose mission is to improve people's lives with our health care products. We develop, manufacture and market a range of pharmaceutical, medical device and over-the-counter products, primarily in the therapeutic areas of eye health, gastroenterology and dermatology. We are delivering on our commitments as we build an innovative company dedicated to advancing global health. More information can be found at www.bauschhealth.com.
Forward-looking Statements This news release may contain forward-looking statements, which may generally be identified by the use of the words "anticipates," "expects," "intends," "plans," "should," "could," "would," "may," "will," "believes," "estimates," "potential," "target," or "continue" and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, risks and uncertainties discussed in the Company's most recent annual or quarterly report and detailed from time to time in the Company's other filings with the Securities and Exchange Commission and the Canadian Securities Administrators, which factors are incorporated herein by reference. In addition, certain material factors and assumptions have been applied in making these forward-looking statements, including that the risks and uncertainties outlined above will not cause actual results or events to differ materially from those described in these forward-looking statements. The Company believes that the material factors and assumptions reflected in these forward-looking statements are reasonable, but readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. Bausch Health undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this news release or to reflect actual outcomes, unless required by law.
Investor/Media Contact: Arthur Shannonarthur.shannon@bauschhealth.com(514) 856-3855(877) 281-6642 (toll free)
https://mma.prnewswire.com/media/948779/BAUSCH_HEALTH__Logo.jpg
https://c212.net/c/img/favicon.png?sn=NY16783&sd=2019-07-17
View original content to download multimedia:http://www.prnewswire.com/news-releases/court-upholds-the-validity-and-determined-actavis-infringement-of-patent-protecting-relistor-tablets-300887079.html
SOURCE Bausch Health Companies Inc.
https://rt.prnewswire.com/rt.gif?NewsItemId=NY16783&Transmission_Id=201907171941PR_NEWS_USPR_____NY16783&DateId=20190717
Stock Symbols TEVA
← European High Growth Opportunities Securitization Fund Closes Second Tranche of Financing Arrangement with Alternate Health Corp.
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Verb Technology Company, CannTrust Holdings, Realogy Holdings, and Reckitt Benckiser and Encourages Investors to Contact the Firm →
Researchers aim to Build Credibility for CBD Products Following Shift in Regulations
Zynerba Pharmaceuticals Added to Russell 2000(R) and 3000(R) Indexes
CBD Based Treatments Grow in Popularity as Regulators Soften Stance
Continued Legalization Efforts Aid the Cannabis Market's Global Expansion
Cannabis Consumers Reap the Rewards of Evolving Cultivation Techniques
Zynerba Pharmaceuticals Receives New U.S. Patent for Treatment of Autism Spectrum Disorder with Cannabidiol
Star Power and Craft Cultivation Add New Dimensions to the Cannabis Market
Zynerba Pharmaceuticals to Present at FDA's Public Hearing on Scientific Data and Information about Products Containing Cannabis or Cannabis-derived Compounds
Flourishing Cannabis Companies Seek to Fill Corporate Roles
International Regions are Warming up to the CBD and Cannabis Industry